AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Film-coated tablet
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Film-coated tablet
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Tablet
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Tablet
Study NCT01657838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01657838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: oral
Study NCT00998504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resVida
Description: resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
Study NCT00998504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
Study NCT02499848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single prostate cancer lesion injected with PRX302.
Study NCT03124277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortifit®
Description: Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
Study NCT03124277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Best local diet
Study NCT03246451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2-4 tablets in 14 days
Study NCT03246451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000-2000 mg in 14 days
Study NCT03246451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 9 mg/ml saline infusion during experimental days
Study NCT03246451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Infusion of GLP-1 receptor antagonist used as a tool during experimental days
Study NCT05209139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice placebo
Description: One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone gel
Description: Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol Solution
Description: Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ethanol Solution
Description: Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone placebo (vaseline)
Description: Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone placebo (vaseline)
Description: Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ethanol placebo (lemon-flavoured water)
Description: Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
Study NCT04166786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol placebo (lemon-flavoured water)
Description: Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
Study NCT01087918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAGT
Description: 16 sessions / 4 times/week / 45 minutes Lokomat training
Study NCT01087918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: 16 sessions / 4 times/week / 45 minutes lower extremity strength training
Study NCT01628731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
Study NCT01628731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethacrynic acid
Description: ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
Study NCT03247569 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution, single dose
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose suspension, doses range 125 to 500 mg, single dose
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: suspension, single dose
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose or simethicone suspension, 500 mg dose, single dose
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Simethicone or methylcellulose suspension, up to 1500 mg, single dose
Study NCT01940705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing-Aid Informational Guide
Description: Printed take-home guide on hearing aids
Study NCT01940705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing-Aid DVD
Description: Take-home DVD about hearing aids
Study NCT01940705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back Technique
Description: Counseling/Educational session using the teach-back technique to review information about their hearing aids
Study NCT03533335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
Study NCT03533335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
Study NCT03533335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
Study NCT02392559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Dose of subcutaneous evolocumab every 4 weeks
Study NCT02392559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose of subcutaneous placebo treatment every 4 weeks
Study NCT03176511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Matter of Balance plus Dual-Task Balance Challenge Group
Description: Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
Study NCT03176511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Matter of Balance Group
Description: Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo administration
Description: Given topically
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: Given topically
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Given IV
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Given IV
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl citrate
Description: Given IV
Study NCT01516684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl citrate
Description: Given IV
Study NCT04661163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
Study NCT02174549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: Intra-arterial injection into the tumor feeding artery
Study NCT02174549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Embolization (TAE)
Description: Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
Study NCT03594175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUSA-081
Description: Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
Study NCT03594175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
Study NCT03594175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
Study NCT03413722 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: The patient's physician will prescribe drug according to standard practice.
Study NCT03413722 — intervention group
Intervention type: DRUG
Intervention: Everolimus
Description: The patient's physician will prescribe drug according to standard practice.
Study NCT04112667 — intervention group
Intervention type: OTHER
Intervention: Normal Macular Health
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Study NCT04112667 — intervention group
Intervention type: OTHER
Intervention: Early Macular Degeneration
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Study NCT04112667 — intervention group
Intervention type: OTHER
Intervention: Young Normals
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Study NCT01940705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist
Study NCT01940705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist
Study NCT01108744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: 3% hypertonic saline, dosed by ideal patient weight
Study NCT01108744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol 20% intravenous solution, dosed by patient's ideal body weight
Study NCT03006328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM
Description: Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
Study NCT03006328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
Study NCT00497926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoietic Stem Cell Infusion
Description: Enriched Hematopoietic Stem Cell Infusion
Study NCT01802411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL 266 mg
Study NCT01802411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02663128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT04689113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incontinence Health Belief Development Program
Description: After the applied interventions, it is desired to develop kegel exercise behavior in women.
Study NCT04285892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Description: CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house.
Study NCT02977377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
Study NCT02977377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
Study NCT03325413 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic inclusion of family members
Description: Systematic inclusion of family members/ reference person in the perioperative process
Study NCT03325413 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preoperative information
Description: Detailed preoperative information about delirium prevention and procedures
Study NCT03325413 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical and breathing exercises
Description: Preoperative execution of physical and breathing exercises if necessary
Study NCT03325413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary supplements
Description: Dietary supplements if necessary
Study NCT03325413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of long-term medication
Description: Avoidance of unsuitable drugs for elderly if possible
Study NCT03325413 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia whenever possible
Study NCT03325413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personal aids
Description: Personal orientation aids until anesthesia induction
Study NCT03325413 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature management
Description: Perioperative warming
Study NCT03325413 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neurmonitoring
Description: Using Bispectral index (BIS) to measure the depth of anesthesia
Study NCT03325413 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pain catheter
Description: A pain catheter will be used as postoperative pain therapy if possible
Study NCT03930745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal inserts.
Study NCT03930745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL-463
Description: TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
Study NCT06341244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Stacking Technique
Description: To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
Study NCT02670629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial reduction with overriding position
Description: The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
Study NCT02670629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed anatomic reduction
Description: The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
Study NCT01175655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSC
Description: mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
Study NCT03705754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carbon black suspension colonic tattoo injection
Description: Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
Study NCT06650917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the experiment group were treated acupoint massage combined with ear point pressing beans
Description: Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday.
Study NCT03265405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose prednisolone
Description: An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.